Dyadic International Inc. (DYAI)
NASDAQ: DYAIHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
DYAI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $17.80M
- EPS (TTM)
- -$0.23
- Dividend yield
- None
- 52-week range
- 0.34 – 1.60
- Day range
- 0.44 – 0.462
- Volume / Avg
- 119.26K / 201.91K
- Beta
- —
- Shares outstanding
- 40.06M
52-week range
DYAI stock today
Shares of Dyadic International (DYAI) finished lower on Oct 8 at $0.4444, a drop of 2.65% or $0.0121 per share, versus the S&P 500's 0.47% decline. Shares are 72.2% below their 52-week high of $1.60, set on Jul 22, 2026 and 30.7% above the 52-week low of $0.34, near the bottom of the past year's range. DYAI is down 52.7% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 60.7%.
Dyadic International has posted a net loss over the last twelve months (EPS of -$0.23), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Dyadic International
Company profileDyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Mark A. Emalfarb
- Headquarters
- Jupiter, FL
- Employees
- 5
- Website
- dyadic.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$5.50+1137.62%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Dyadic International peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NCELNewcelX Ltd. | 3.11 | +2.47% | $17.96M | vs DYAI |
| NEUPNeuphoria Therapeutics Inc. | 3.35 | -2.05% | $18.13M | vs DYAI |
| ESLAEstrella Immunopharma Inc. | 0.4175 | -0.43% | $18.16M | vs DYAI |
| ICUSeaStar Medical Holding Corporation | 3.49 | -6.18% | $18.36M | vs DYAI |
| AKTXAkari Therapeutics plc ADS | 8.13 | -5.74% | $18.58M | vs DYAI |
| JSPRJasper Therapeutics Inc. | 0.56 | -1.70% | $18.63M | vs DYAI |
| ACTUActuate Therapeutics Inc. | 0.679 | -6.24% | $16.31M | vs DYAI |
| RADXRadiopharm Theranostics Limited ADR | 1.11 | -3.48% | $16.20M | vs DYAI |
Indexes, lists and sector
Appears in lists
Dyadic International stock FAQ
What is Dyadic International's stock price today?
DYAI last traded at $0.4444 as of Oct 8, 4:00 PM EDT, down 2.65% on the day. Prices are delayed at least 15 minutes.
Who is Dyadic International's CEO?
Mr. Mark A. Emalfarb is the chief executive officer of Dyadic International Inc., which has about 5 employees.
What is the DYAI 52-week high?
The 52-week high for DYAI is $1.60 and the 52-week low is $0.34. The stock is currently 72.2% below its high.